Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 6737 - 6744 of 12094 results

Calculating Patent Term Adjustment: Part 2
September 21, 2017| Blog| Viewpoint

New Jersey Supreme Court Reminder - Don’t Forget about the Corporate Practice of Medicine
September 21, 2017| Blog| Viewpoint

Seasoned Litigator Nominated to Replace Commissioner Robinson and Establish Republican Majority at CPSC
September 21, 2017| Blog| Viewpoint

Am I Being Clear Enough? - PTAB Reaffirms Lower Pre-Issuance Threshold for Indefiniteness in Ex Parte McAward
September 20, 2017| Blog| Viewpoint

Tennessee Department of Health Grants COPA Request for Health Care Alliance
September 20, 2017| Blog| Viewpoint

FY2019 Diversity Lottery Instructions Are Now Available
September 20, 2017| Alert| Viewpoint

HHS Watchdog to Probe Medicaid Health Homes Program
September 20, 2017| News

Patent For Cholesterol Drug Livalo Is Valid, Judge Rules
September 20, 2017| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
